GLP-1 Injections in 2026: Cost, Side Effects, Risks & Weight Loss Results

GLP-1 and GIP-GLP-1 injections are prescription drugs for type 2 diabetes, chronic weight management, or both. Semaglutide, tirzepatide, liraglutide, and dulaglutide sit in this family. One brand name got famous. The class is larger. They can help the right patients. They also have labeled risks that social media usually skips.

These pens should come from a family doctor or primary-care clinician, with a clinical dietitian involved, and only if you meet the medical and insurance criteria. A health fund like Clalit in Israel is a useful example: insurance often covers part of the price, not the whole bill, and continuation is not automatic.

This article is about injections in 2026: cost, side effects, labeled risks, and weight-loss results from large trials of Ozempic, Wegovy, Mounjaro, and Zepbound. It is educational, not medical advice. Do not start, stop, or change a dose without the clinician who prescribes it.

Disclosure: SmartEat is a nutrition app. We do not sell or prescribe these drugs. We do help people track protein and fiber when appetite drops, and book a certified nutritionist when the diet is the hard part.

What changed in 2026?

The URL says 2026 because several things actually moved this year. Three that matter for readers:

• Medicare GLP-1 Bridge. From 1 July 2026 through 31 December 2027, eligible Medicare Part D beneficiaries can access certain FDA-approved weight-management GLP-1s for a $50 monthly copay under a CMS demonstration. Covered products include Wegovy (injection and tablet) and Zepbound KwikPen. Ozempic, Mounjaro, compounded copies, and some Zepbound presentations are not in the Bridge. It is not automatic: a prescriber has to submit prior authorization, and the $50 does not count toward the usual Part D out-of-pocket cap. See the CMS announcement.
• Suicide-warning language came off obesity labels. In January 2026 the FDA requested removal of suicidal behavior and ideation warnings from Wegovy, Zepbound, and Saxenda after a review found no increased risk in the available evidence. That is not a claim that mood changes never happen. New depression, suicidal thoughts, or a sudden behavior change still belongs with a clinician the same day.
• Wegovy now has an FDA-approved oral tablet (once-daily semaglutide, U.S. launch in early 2026). This article focuses on injections. The tablet is a different device, dose schedule, and counseling conversation. Rybelsus remains the older oral semaglutide brand for type 2 diabetes, not a weight-management pen.

What these injections do

GLP-1 receptor agonists copy a gut hormone that helps the pancreas release insulin when glucose is high, slows how fast the stomach empties, and reduces appetite. Tirzepatide also activates GIP receptors. That is why people eat less without "trying harder" in the usual sense - and why greasy meals, big portions, and skipped protein become a nutrition problem, not a willpower problem.

They are not a vitamin, a detox, or a cosmetic shortcut. Using a diabetes pen for weight loss without that indication is a clinical decision, not a lifestyle hack. Regulators register specific brand names for specific uses. Match the box to the prescription.

Who should prescribe this

This is not a product you pick up because a friend had a good month. The path that belongs in a clinic is:

• Family doctor first. In Clalit, the usual start for a subsidized weight-management pen is the family physician: current BMI, medical history, and a computerized approval - not a social-media seller.
• Dietitian recommendation and follow-up. The labeled use is "with a reduced-calorie diet and more activity." Funds often require dietitian accompaniment. A nutritionist recommendation is part of treating this as a medical plan, not a shortcut around food.
• Meet the criteria. For weight-management pens, that is typically BMI 30 or above, or BMI 27-30 with a related condition (type 2 diabetes, prediabetes, high blood pressure, abnormal lipids, sleep apnea, or heart disease). A few extra kilos for a wedding is not an indication. Type 2 diabetes pens in the national basket have their own HbA1c, BMI, and "failed other pills" rules.

If your fund asks for a specialist, blood tests, or a waiting period, that is the process - not optional fine print.

Brand comparison

Brand names are not interchangeable even when the molecule looks similar. In the U.S., Mounjaro is the tirzepatide diabetes brand. Zepbound is the tirzepatide brand approved for chronic weight management, and it also has an FDA indication for moderate-to-severe obstructive sleep apnea in adults with obesity. Dose, device, approved use, and price differ. Prices below are approximate 2026 list / reported private figures - confirm at the pharmacy.

Rybelsus is daily oral semaglutide for type 2 diabetes (U.S. list about $1,030/month; Israel about ₪454 for 14 mg, 30 tablets). It is not an injection. If your clinician named a brand you do not see here, ask which molecule it is. The risk list below is class-overlapping, with extra notes where labels differ.

How to read the prices

Without insurance, the main weekly pens in the United States usually list around $1,000-1,350 a month (about $12,000-16,200 a year at those list prices). Commercial insurance plus a manufacturer savings card can drop that to about $25 for people who qualify. Direct cash programs are often in the $199-499 range. Eligible Medicare Part D members may pay $50/month for Bridge-covered weight-management products from July 2026.

In Israel, private annual cost depends on the brand. Ozempic private is on the order of ₪4,800/year. Wegovy private is about ₪9,100-15,000/year. Mounjaro private at ~₪1,774/month is about ₪21,300/year - not the same as Wegovy. Complementary insurance (Clalit is the example below) covers part of the bill if you meet BMI rules and keep showing results. Prices move by dose and date. Confirm at the pharmacy with your prescription.

Insurance and continuation (Clalit as an example)

In the US, coverage is mostly a plan-and-prior-authorization question: diabetes pens are covered more often than obesity pens. In Israel, most adult weight-management pens are not in the national health basket. People pay complementary insurance (SHABAN) or full private price. Clalit is the largest fund. Typical eligibility for a subsidized weight pen: BMI 30 or above, or BMI 27-30 with a related condition. Start with the family doctor, current BMI, computerized approval. Reporting on Clalit Mushlam Wegovy described a 50% subsidy for eligible Mushlam members (about ₪290-627/month depending on dose).

Clalit does not hand you a lifetime discount. Reporting describes a waiting period of about three months, then ongoing approval that depends on sticking with the plan, dietitian follow-up, and losing at least about 5% of starting weight. If the scale does not move, or the weight comes back, the fund can refuse to continue the subsidy. US insurers use similar "show a result or we stop paying" rules. Labels make the same logic medical - Wegovy's leaflet says adolescents should stop if BMI has not fallen at least 5% after 12 weeks on the 2.4 mg (or maximum tolerated) dose; Saxenda's class rule is similar for adults who do not lose about 5% after 12 weeks on the full dose.

A 50% insurance cut still leaves a real monthly bill, plus dietitian visits and labs. Stopping the pen without a food plan is how a lot of the lost weight returns - which is also how continuation approvals die.

What large trials actually showed

These numbers are averages from randomized trials, not a promise for one person. Lifestyle support was part of the protocols.

• STEP 1 (NEJM, 2021): In adults with overweight or obesity, weekly semaglutide 2.4 mg plus lifestyle intervention led to a mean weight change of -14.9% at 68 weeks, versus -2.4% with placebo. A DXA substudy found a greater drop in fat mass than in lean mass - lean tissue still fell, which is why protein and resistance training matter if your clinician says they are safe.
• SELECT (NEJM, 2023): In 17,604 adults with overweight or obesity and existing cardiovascular disease but without diabetes, weekly semaglutide 2.4 mg reduced a composite of cardiovascular death, nonfatal heart attack, or nonfatal stroke by 20% versus placebo (hazard ratio 0.80) over a mean 39.8 months. More people stopped the drug for side effects than stopped placebo (16.6% vs 8.2%), mainly gut symptoms.
• SURMOUNT-1 (NEJM, 2022): In adults with obesity (without diabetes), weekly tirzepatide at 72 weeks produced mean weight change of -15.0% (5 mg), -19.5% (10 mg), and -20.9% (15 mg), versus -3.1% with placebo on the treatment-regimen analysis. Most common side effects were gastrointestinal, usually during dose increases.

Those trials are why clinicians take the class seriously for the right medical indications. They are also why "everyone at the office is on it" is not an indication.

Common side effects (the ones trials see often)

FDA labels for Ozempic list nausea, vomiting, diarrhea, abdominal pain, and constipation as the most common adverse reactions (reported in 5% or more of treated patients in trials). The same gut pattern shows up across Wegovy, Mounjaro, and Zepbound. Symptoms often peak when the dose goes up and ease for many people later. "Often" is not "harmless." Persistent vomiting, inability to keep fluids down, or severe abdominal pain is a reason to contact a clinician the same day - not to wait for the next refill.

Because the stomach empties more slowly, fatty, fried, and very large meals are frequent triggers. Alcohol can hit harder on a small intake. That is a labeled delay of gastric emptying, not a personality flaw.

Serious risks that belong on the consent conversation

The following are on U.S. prescribing information for semaglutide and/or tirzepatide products, or in European regulator updates. They are uncommon compared with nausea. They are not theoretical blog rumors.

• Boxed warning - thyroid C-cell tumors in rodents. GLP-1 and GIP/GLP-1 injectables carry an FDA boxed warning because rodent studies found thyroid C-cell tumors. It is not proven that this happens in humans. These drugs are contraindicated if you or a close family member has had medullary thyroid carcinoma, or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Report a neck mass, trouble swallowing, shortness of breath, or persistent hoarseness.
• Pancreatitis. Acute pancreatitis has been observed with GLP-1 receptor agonists. Labels say to stop the drug if pancreatitis is suspected and not to restart if it is confirmed. Severe, persistent upper abdominal pain, with or without vomiting, needs urgent care.
• Gallbladder disease. Gallstones and cholecystitis occurred more often on drug than placebo in trials. Rapid weight loss itself raises gallstone risk. Right-upper-abdominal pain, fever, or yellowing of the skin or eyes needs a medical workup.
• Ileus and severe gut slowing. The FDA added ileus (intestinal blockage) to semaglutide labels after postmarketing reports. Wegovy's label also warns about severe gastrointestinal reactions and says it is not recommended in severe gastroparesis. Severe constipation, inability to pass stool or gas, or a swollen, painful abdomen is an emergency pattern - not "the drug is working."
• Kidney injury from dehydration. Vomiting and diarrhea can deplete volume. Labels tell clinicians to watch kidney function when that happens.
• Low blood sugar when combined with insulin or a sulfonylurea. The GLP-1 itself is glucose-dependent; the combination is not automatically safe. Dose changes belong to the prescriber.
• Oral hormonal contraceptives and tirzepatide. Zepbound and Mounjaro can reduce the effectiveness of oral birth-control pills after treatment starts and after each dose increase, because the stomach empties more slowly. Current labeling advises switching to a non-oral method or adding barrier contraception for four weeks after initiation and four weeks after each dose escalation. Non-oral hormonal methods are not expected to have the same problem. This is a same-week conversation with the prescriber, not a footnote to read later.
• Diabetic retinopathy complications. In a two-year trial in high-risk type 2 diabetes, retinopathy complications were more common with semaglutide (3.0%) than placebo (1.8%), with a larger gap in people who already had retinopathy. Rapid glucose improvement can temporarily worsen retinopathy. Eye history matters before and during treatment.
• NAION (very rare, EMA 2025). The European Medicines Agency concluded that non-arteritic anterior ischemic optic neuropathy is a very rare side effect of semaglutide (Ozempic, Rybelsus, Wegovy) - up to about 1 in 10,000 people. Sudden vision loss needs urgent eye care. If NAION is confirmed, EMA says treatment should stop.
• Aspiration under anesthesia. Because the stomach may still hold food, labels warn about pulmonary aspiration during general anesthesia or deep sedation. Tell the surgical and anesthesia team you are on a GLP-1 before any procedure. Do not invent your own "hold for two weeks" plan unless they give one.
• Pregnancy and planning pregnancy. Animal studies showed reproductive toxicity. Human data are limited. Labels say to discontinue semaglutide at least two months before a planned pregnancy because of the long washout. Do not use these drugs to "get in shape" while trying to conceive.
• Serious allergic reactions (anaphylaxis, angioedema) have been reported. Stop and get emergency care if swelling of the face, tongue, or throat, or trouble breathing starts.

Muscle and bone are not a boxed warning, but they are a real nutrition issue. A share of lost weight can be lean mass. That is why we already published a separate plate guide: What to eat on a GLP-1.

After you stop

Appetite usually returns. In the STEP 1 extension, people who stopped weekly semaglutide after 68 weeks regained a large share of the lost weight over the following year. That is expected pharmacology, not a moral failure. It is also how continuation approvals die: if the weight comes back, Clalit-style subsidies often do not. If the plan is a short "reset," ask the prescriber what the off-ramp looks like - food, activity, and follow-up - before the last pen.

Compounded and unapproved copies

The FDA has stated that compounded semaglutide and tirzepatide products are not FDA-approved and do not go through the same premarket review for safety, quality, or effectiveness. The agency has received reports of adverse events after compounded products, including dosing errors when people drew up doses from vials instead of using a labeled pen. Some products have used salt forms of semaglutide that are not the approved active ingredient. After U.S. shortages of tirzepatide and semaglutide were resolved (late 2024 and February 2025), the legal room to copy these drugs narrowed.

Buy only from a licensed pharmacy filling a real prescription. "Research use only," spa pens, and social-media vials are not a clinical trial.

Who should not treat this as a DIY project

Talk to a family doctor first - and skip internet dosing - if any of this applies: personal or family history of medullary thyroid cancer or MEN 2; past pancreatitis; severe gastrointestinal disease or known gastroparesis; pregnancy, breastfeeding, or plans to conceive soon; type 1 diabetes (these are not insulin); eating-disorder history; or you are already on insulin or a sulfonylurea. Apps cannot clear those questions. Neither can a leftover pen.

If you are already on a prescribed pen and food intake has collapsed, that is a dietitian conversation as much as a refill conversation. See when to see a dietitian vs a nutrition app and booking a certified nutritionist in the app.

Bottom line

These injections are among the best-studied tools we have for type 2 diabetes and, at the right brand and dose, for chronic weight management and some heart-risk reduction. They belong with a family doctor, a dietitian, and criteria you actually meet. Insurance typically pays part of the price and keeps paying only if there are results - roughly 5% down, not regain. US list prices are usually about $1,000-1,350 a month; Israel private cost depends on the brand (Wegovy and Mounjaro are not the same annual bill). The evidence is in NEJM-scale trials, not in before-and-after photos. The risks are on the label. A licensed prescriber plus a real food plan is the research-based path. A vial from a stranger is not.

Educational only. Not medical advice. Prices and insurance rules change by country, dose, date, and your personal eligibility - check with your clinician and the pharmacy. Read the patient leaflet that comes with your pen. Report suspected side effects through your national reporting system (in the U.S., FDA MedWatch; in Israel, the Ministry of Health).

Sources used for this article:

• Ozempic (semaglutide) U.S. prescribing information
• Wegovy (semaglutide) U.S. prescribing information, DailyMed
• Mounjaro (tirzepatide) U.S. prescribing information
• Zepbound (tirzepatide) U.S. prescribing information (weight management, OSA, oral-contraceptive warning)
• Wilding et al. STEP 1. N Engl J Med. 2021. Mean -14.9% vs -2.4% at 68 weeks.
• Lincoff et al. SELECT. N Engl J Med. 2023. MACE hazard ratio 0.80 in 17,604 adults.
• Jastreboff et al. SURMOUNT-1. N Engl J Med. 2022. Tirzepatide -15.0% / -19.5% / -20.9% vs -3.1% placebo at 72 weeks.
• FDA, January 2026: request to remove suicidal behavior/ideation warning from Wegovy, Zepbound, and Saxenda.
• CMS Medicare GLP-1 Bridge: $50 monthly copay for eligible Part D beneficiaries, 1 July 2026-31 December 2027.
• EMA PRAC, 2025: NAION listed as a very rare side effect of semaglutide medicines.
• FDA on compounded (not FDA-approved) semaglutide and tirzepatide
• Clalit Mushlam Wegovy subsidy reporting (Jerusalem Post / Clalit announcement coverage).

Related reading:

• What to eat on a GLP-1: protein, fiber, muscle
• When to see a dietitian vs a nutrition app
• Book a certified nutritionist in the app
• Download SmartEat